+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anticoagulant Reversal Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 120 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5707272
Description Jump to:

Industry Outlook

The global anticoagulant reversal drugs market expected to grow at compound annual growth rate (CAGR) of 15.3% during the forecast period from 2022 to 2030. Reversing the effects of anticoagulants including novel oral anticoagulants (NOACs), Vitamin K antagonist and others is a major concern in clinical practice especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in last decade has increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT). However, this growth in anticoagulants usage has led to the rise in the incidence of hospitals admissions and death due to increased bleeding due to anticoagulation. According to Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in U.S. alone and close to 2,000 deaths per month attributable to anticoagulation or factor Xa inhibitor related bleeding. These factors have led to furious research and development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) has granted special status and accelerated approvals for development and swift market entry of certain anticoagulant antidotes.

Recent Approval of First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market

In May 2018, The U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing of anticoagulation effects. Andexxa received both orphan drug status and breakthrough designation by U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it to grow at fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drugs market owing to increased use of these agents during critical situation. Idarucizumab, approved in 2015 was the only drug for reversing the anticoagulation effects of dabigatran etexilate mesylate.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anticoagulant Reversal Drugs market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Anticoagulant Reversal Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Prothrombin Complex Concentrates (PCC)
  • Vitamin K
  • Protamine
  • Tranexmic Acid
  • Desmopressin
  • Idarucizumab
  • Andexxa
  • Pipeline Analysis
  • Phase III Drugs (Forecast till 2026)
  • Octaplex
  • Phase I and II Drugs (Tabular Representation)

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Anticoagulant Reversal Drugs market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Anticoagulant Reversal Drugs market?
  • Which is the largest regional market for Anticoagulant Reversal Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Anticoagulant Reversal Drugs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Anticoagulant Reversal Drugs market worldwide?

This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Anticoagulant Reversal Drugs Market
2.2. Global Anticoagulant Reversal Drugs Market, By , 2021 (US$ Million)
2.3. Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021 (US$ Million)
2.4. Global Anticoagulant Reversal Drugs Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021
3. Anticoagulant Reversal Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Anticoagulant Reversal Drugs Market Vendors
3.2. Strategies Adopted by Anticoagulant Reversal Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Anticoagulant Reversal Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Anticoagulant Reversal Drugs Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
6. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Prothrombin Complex Concentrates (PCC)
6.3.2. Vitamin K
6.3.3. Protamine
6.3.4. Tranexmic Acid
6.3.5. Desmopressin
6.3.6. Idarucizumab
6.3.7. Andexxa
6.3.8. Pipeline Analysis
6.3.9. Phase III Drugs (Forecast till 2026)
6.3.10. Octaplex
6.3.11. Phase I and II Drugs (Tabular Representation)
7. North America Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
7.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
7.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
7.4.1.1.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
7.4.1.2.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
7.4.1.3.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
8. UK and European Union Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
8.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
8.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
8.4.1.1.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
8.4.1.2.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
8.4.1.3.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
8.4.1.4.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
8.4.1.5. France
8.4.1.5.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
8.4.1.5.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
8.4.1.6.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
9. Asia Pacific Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
9.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
9.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
9.4.1.1.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
9.4.1.2.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
9.4.1.3. India
9.4.1.3.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
9.4.1.3.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
9.4.1.4.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
9.4.1.5.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
9.4.1.6.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
10. Latin America Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
10.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
10.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
10.4.1.1.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
10.4.1.2.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
10.4.1.3.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
11. Middle East and Africa Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
11.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
11.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
11.4.1.1.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
11.4.1.2.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
11.4.1.3.1. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
12. Company Profile
12.1. Boehringer Ingelheim GmbH
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Fresenius Kabi AG
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Pfizer, Inc.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Bausch Health Companies, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Amneal Pharmaceuticals, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. CSL Behring Limited
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Octapharma AG
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Portola Pharmaceuticals, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Perosphere Pharmaceuticals, Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Ferring Pharmaceuticals
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
List of Figures
Figure 1 Global Anticoagulant Reversal Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Anticoagulant Reversal Drugs Market: Quality Assurance
Figure 5 Global Anticoagulant Reversal Drugs Market, By , 2021
Figure 6 Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021
Figure 7 Global Anticoagulant Reversal Drugs Market, By Geography, 2021
Figure 8 Market Geographical Opportunity Matrix - Global Anticoagulant Reversal Drugs Market, 2021
Figure 9 Market Positioning of Key Anticoagulant Reversal Drugs Market Players, 2021
Figure 10 Global Anticoagulant Reversal Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 11 Global Anticoagulant Reversal Drugs Market, By , 2021 Vs 2030, %
Figure 12 Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021 Vs 2030, %
Figure 13 U.S. Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 14 Canada Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 15 Rest of North America Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 16 UK Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 17 Germany Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 18 Spain Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 19 Italy Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 20 France Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 21 Rest of Europe Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 22 China Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 23 Japan Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 24 India Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 25 Australia Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 26 South Korea Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 27 Rest of Asia Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 28 Brazil Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 29 Mexico Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 30 Rest of Latin America Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 31 GCC Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 32 Africa Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
Figure 33 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 2 Global Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 3 North America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 4 North America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 5 U.S. Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 6 U.S. Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 7 Canada Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 8 Canada Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 9 Rest of North America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 10 Rest of North America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 11 UK and European Union Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 12 UK and European Union Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 13 UK Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 14 UK Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 15 Germany Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 16 Germany Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 17 Spain Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 18 Spain Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 19 Italy Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 20 Italy Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 21 France Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 22 France Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 23 Rest of Europe Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 24 Rest of Europe Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 25 Asia Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 26 Asia Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 27 China Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 28 China Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 29 Japan Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 30 Japan Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 31 India Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 32 India Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 33 Australia Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 34 Australia Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 35 South Korea Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 36 South Korea Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 37 Latin America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 38 Latin America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 39 Brazil Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 40 Brazil Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 41 Mexico Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 42 Mexico Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 43 Rest of Latin America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 44 Rest of Latin America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 45 Middle East and Africa Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 46 Middle East and Africa Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 47 GCC Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 48 GCC Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 49 Africa Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 50 Africa Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)

Companies Mentioned

  • Boehringer Ingelheim GmbH
  • Fresenius Kabi AG
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • Amneal Pharmaceuticals Inc.
  • CSL Behring Limited
  • Octapharma AG
  • Portola Pharmaceuticals Inc.
  • Perosphere Pharmaceuticals Inc.
  • Ferring Pharmaceuticals

Related Topics

Related Reports

Anticoagulant Reversal Drugs Market by Product, Distribution - Global Forecast 2025-2030 - Product Image

Anticoagulant Reversal Drugs Market by Product, Distribution - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Anticoagulant Reversal Drugs Market Size, Share & Trends Analysis Report By Product Type (Andexanet Alfa, Idarucizumab, Phytonadione (Vitamin K)), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Anticoagulant Reversal Drugs Market 2025-2029 - Product Image

Anticoagulant Reversal Drugs Market 2025-2029

  • Report
  • 157 Pages
  • Global
From
Anticoagulants - Global Strategic Business Report - Product Image

Anticoagulants - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Anticoagulants Market Report 2025 - Product Image

Anticoagulants Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.